



Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, May 20, 2026
Minutes approved by the board on June 17, 2026

Web link to the meeting video: www.youtube.com/watch?v=S1EZJQvWJic

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260520-PDAB-document-package.pdf>

Call to order: Vice Chair Dan Hartung called the meeting to order at 8:00 a.m.

Roll call:

Present: Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman and John Murray

Arrived late: Chair Shelley Bailey (9:30 a.m.)

Absent: None

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: Chris Laman and John Murray provided statements. View at video minute [00:02:08](#).

Public comments: The board heard comments from Stacy Sanders and Rami Major of Sen. Ron Wyden's office. The comments were moved earlier in the agenda to accommodate schedules in Washington, D.C. View at video minute [00:04:19](#).

Approval of board minutes: Vice Chair Hartung approved by consensus the April 15, 2026, minutes as shown on [Pages 2-3](#) of the agenda materials. View at video minute [00:18:38](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute [00:19:08](#).

Public comment periods: At board meetings in May through August during the drug review process, the board will provide two public comment periods: one for general comments and another for comments about prescription drugs under review.

General comments: At the May 20 meeting, the board provided extended time for each speaker. Additionally, after calling on the people who signed up in advance to speak, the board vice chair asked if anyone from the audience wanted to speak. Eleven people spoke to the board: Joel Nista, consumer; Tiffany Westrich-Robertson, EACH/PIC Coalition; Lee Bliven II, AARP; Lorren Sandt, Caring Ambassadors Program; Derek Flowers, Value of Care Coalition; Primo Castro, BIO; Laura Packard, Voices of Health Care Action; Chris Coughlin, Oregon Consumer Justice; and Charlie Fisher, OSPIRG; Scott Bertani, Health HIV; and Joanna Wilson,



consumer (speaking through ASL interpreters Krystle Kuester and Susie Friberg). View the general public comments at [00:37:07](#).

The board received letters from: Carolina Sommers, Rare Disease Network; Jennifer Irby, Beaverton Pharmacy; Dharia McGrew and Alexandria Hussey, PhRMA; Patricia Pomeroy; Gail Lovelace Menasco; and Tiffany Westrich-Robertson, EACH/PIC Coalition. The letters are posted on the [PDAB website](#).

Drug review public comment: At the May 20 meeting, the board provided extended time for each speaker. Terri Lee of Merck spoke about Keytruda and the drug review process. The board received letters from: Jane Leo, American Cancer Society Cancer Action Network – Keytruda, Verzenio; Suzanna Masartis, Community Liver Alliance – Keytruda; Tom Brownlie, Pfizer – Xeljanz; Helen Fitzpatrick – AbbVie – Skyrizi; Seth Greiner, National Multiple Sclerosis Society – Ocrevus; Timothy Layton, Genentech – Ocrevus, Xolair; Terri Lee and Christin O’Neill, Merck – Keytruda; Michael Eging, Rare Access Action Project – Keytruda. The letters are posted on the [PDAB website](#).

Discussion about drug review road map, drug review report formatting and structure: Cortnee Whitlock, senior policy analyst, discussed the roadmap and timeline for the drug review process. She also discussed the feedback forms and the report format and structure for the drug review process. View the discussion at video minute [02:08:03](#).

Announcements: Chair Bailey announced the next board meeting will be June 17, 2026, at 8 a.m. View at video minute [03:42:37](#).

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at video minute [03:42:53](#).